![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Drug Research
Abbvie and principia announce collaboration on oral immunoproteasome inhibitors
AbbVie , a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, announced today that they have entered a collaboration for...
Drug Research
Thermo Fisher Scientific and SRI International Collaborate to Enhance Small Molecule Research
Thermo Fisher Scientific Inc., the world leader in serving science, and SRI International, a research center that creates world-changing solutions, today announced the results...
Drug Research
eTheRNA advances in-vivo mRNA cancer immunotherapy into first oncology clinical studies
eTheRNA immunotherapies, a clinical-stage company developing mRNA based cancer immunotherapies from its unique TriMix platform, announces the start of the first Phase Ib oncology...
Drug Research
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China
Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate...
Drug Research
Sandoz receives approval in Europe for Rixathon® to treat blood cancers and immunological diseases
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the EC  has approved Rixathon® (biosimilar rituximab*) for use...
Drug Research
Numerate and Takeda Enter Agreement to Generate Novel Clinical Candidates Using AI-Driven Drug Discovery
Numerate, Inc., a computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery, announced the formation of...
Drug Research
Eisai Enters Into Joint Research Agreement With The Broad Institute To Develop An Antimalarial Medicine
Eisai Co Ltd announced that it has entered into a new joint research agreement with the Broad Institute , a collaborative research institute which...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read